This downregulation of MSH2 by TGF-β also contributes to resistance to DNA-damaging chemotherapy agents in cancer cells, as MSH2 is required for the recognition of drug-induced DNA damages, which triggers apoptosis [55]. This evidence concerns the gene MSH2 and cancer.